
Defence Therapeutics Inc.
Defence Therapeutics Inc. (DTC.CN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
dtc.cn · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Defence Therapeutics Inc.You DTC.CN | $29M | N/A | — | -$0.11 |
DIAGNOS Inc. ADK.V | $22M | N/A | — | -$0.05 |
BriaCell Therapeutics Corp. BCT.TO | $8M | N/A | — | -$62.95 |
The Cannabist Company Holdings Inc. CBST.NE | $17M | N/A | — | -$0.23 |
Gemina Laboratories Ltd. GLAB.CN | $5M | N/A | — | -$0.06 |
Microbix Biosystems Inc. MBX.TO | $39M | N/A | — | -$0.02 |
MedMira Inc. MIR.V | $42M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Defence Therapeutics Inc. (DTC.CN) measures how much investors pay for each dollar of the company's trailing earnings. DTC.CN's current PE ratio of N/A is calculated by dividing its stock price of $0.50 by its TTM earnings per share of -$0.11.
Frequently asked questions
DTC.CN pe ratio · 6 questionsDTC.CN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.50 and TTM EPS of -$0.11. Data sourced from Financial Modeling Prep via DTC.CN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Defence Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09